Anthropic acquires biotech startup Mithril Medicine and launches in-house drug discovery
Anthropic has acquired one-person biotech startup Mithril Medicine and unveiled partnerships with six organizations to deploy its Claude AI across preclinical drug discovery and operations.
Anthropic has launched internal drug discovery programs after acquiring Mithril Medicine, a one-person biotechnology company developing treatments for two rare forms of muscular dystrophy. According to reports on the acquisition, which took place in July 2026, founder Cody Tranbarger utilized Anthropic's AI model Claude to manage operations, contracts, logistics, and experiments across 11 external laboratories. The approach advanced a potential therapy from an initial concept to promising results in mice in under 18 months.[2][4]
Tranbarger is continuing the research at Anthropic, where he plans to initiate multiple new research efforts. Anthropic stated that if the experimental candidates continue to hold up, an experimental treatment targeting rare childhood forms of muscular dystrophy could be prepared to enter human clinical trials as early as late 2028.[3][4]
Alongside its internal programs, Anthropic announced research collaborations with six organizations: BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group. Anthropic indicated the partnerships span drug design, manufacturing, regulatory documentation, and clinical trial planning, with the broader aim of utilizing Claude across the operational and scientific stages of medicine development.[1][4]
Key facts
- Anthropic acquired Mithril Medicine, a one-person startup developing treatments for two rare forms of muscular dystrophy, in July 2026.
- Mithril Medicine founder Cody Tranbarger used Claude to coordinate contracts, logistics, and testing across 11 external labs.
- Mithril advanced a potential muscular dystrophy treatment from concept to promising results in mice in under 18 months.
- Anthropic anticipates a drug candidate could reach human clinical trials as soon as late 2028 if research continues successfully.
- Anthropic announced drug discovery partnerships with BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group.
- The partner collaborations cover drug design, manufacturing, regulatory documentation, and clinical trial planning.
Sources · 3 sources
- MT
MTS@MTSlivePost on X ·
SITUATION DETECTED: Anthropic has announced drug discovery partnerships with BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group, and has also begun drug discovery efforts of their own.
Open source - MT
MTS@MTSlivePost on X ·
SITUATION DETECTED: Anthropic acquired a one-person company in July 2026. Mithril Medicine - developing treatments for two rare forms of muscular dystrophy - owned and run by one person who used Claude to organize contracts, logistics, and experiments with 11 external labs.
Open source - CO
Cointelegraph@CointelegraphPost on X ·
🤖 NEW: Anthropic is working with six organizations to accelerate drug development using Claude and has launched its own drug discovery programs targeting rare childhood forms of muscular dystrophy. https://t.co/W7Kc6Gp4nj
Open source - WS
Wall St Engine@wallstenginePost on X ·
Anthropic has acquired Mithril Medicine, a one-person biotech startup, and is now running drug discovery programs of its own. Founder Cody Tranbarger used Claude to coordinate contracts, logistics and experiments with 11 external labs. Anthropic says that work took a potential treatment for a rare form of muscular dystrophy from an idea to promising results in mice in under 18 months. Mithril has been developing treatments for two rare forms of muscular dystrophy. Tranbarger is continuing the research at Anthropic, which says a drug could be ready to start human trials as early as late 2028 if the candidates continue to hold up. Anthropic also announced research partnerships with six organizations, including Bristol Myers Squibb, Generate Biomedicines and Enveda. The work spans drug design, manufacturing, regulatory documentation and clinical trial planning. Most of the research remains preclinical. The broader goal is to use Claude across the scientific and operational work required to move a potential medicine toward patients.
Open source